Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) EBT Margin: 2023-2025

Historic EBT Margin for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -2,582.35%.

  • Mereo BioPharma Group's EBT Margin fell 683193.00% to -2,582.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 13,541.69%, marking a year-over-year increase of 77767503.00%. This contributed to the annual value of 3,157.15% for FY2024, which is 345713.00% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's EBT Margin stood at -2,582.35%, which was down 104.24% from 60,900.00% recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's EBT Margin peaked at 60,900.00% during Q2 2025, and registered a low of -2,582.35% during Q3 2025.
  • Moreover, its 3-year median value for EBT Margin was 1,878.93% (2024), whereas its average is 7,241.31%.
  • The largest annual percentage gain for Mereo BioPharma Group's EBT Margin in the last 5 years was 5,719,758bps (2025), contrasted with its biggest fall of 683,193bps (2025).
  • Mereo BioPharma Group's EBT Margin (Quarterly) stood at -964.10% in 2023, then surged by 284,303bps to 1,878.93% in 2024, then crashed by 683,193bps to -2,582.35% in 2025.
  • Its EBT Margin was -2,582.35% in Q3 2025, compared to 60,900.00% in Q2 2025 and 7,159.44% in Q1 2025.